American Society of Cataract and Refractive Surgery

Tozzi and Wallach discuss ways to omit artificial sweeteners and added sugars from children’s diets and minimize risk for T2D and MASLD later in life.

Shultz discusses the impact of lotilaner ophthalmic solution 0.25% to treat active Demodex blepharitis in patients with meibomian gland dysfunction.

Kendall E. Donaldson, MD, discusses the significant impact of lotilaner ophthalmic solution on symptoms in patients with Demodex blepharitis in the Orion registry.

Shah explores the impact of hyperosmolarity on tear film post-cataract surgery, emphasizing the need for enhanced dry eye management strategies.

A new study highlights rapid relief and high satisfaction with PFHO for dry eye disease, showing significant symptom improvement within minutes.

Trial data reveal phentolamine ophthalmic solution's potential to treat night vision disturbances post-keratorefractive surgery, addressing a critical unmet need.

Phentolamine ophthalmic solution significantly enhances outcomes post-dilation, rapidly returning visual symptoms to baseline levels.

Lifitegrast shows rapid and sustained relief for dry eye disease, with high satisfaction among providers and patients, according to recent findings.

Younger age and recurrent disease significantly increase the risk of pterygium progression, highlighting critical factors for ophthalmologists.

A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.

BRIMOCHOL PF offers lasting near vision improvement for presbyopia, demonstrating robust efficacy and safety in a landmark Phase 3 study.

Travoprost intracameral implant significantly reduces intraocular pressure and medication use in patients with glaucoma over three years.

A Phase 1/2 trial shows promising results for corneal edema, highlighting significant visual and quality of life improvements with an innovative cell therapy.

Long-term analysis confirms lifitegrast's safety for dry eye treatment, showing no new safety signals in nearly 800,000 patient treatment years.

Cyclosporine 0.09% significantly improves dry eye symptoms in patients inadequately treated with lower concentrations, enhancing quality of life.

Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.